Asia’s rise in innovation: a China Healthcare Summit preview

BayHelix’s Guo-Liang Yu and McKinsey’s Josie Zhou join the BioCentury This Week podcast to discuss cross-border innovation and deal flow in the biopharma sector during a preview of the upcoming BioCentury-BayHelix China Healthcare Summit.

The summit kicks off at a time of record cross-border deals and validating comments from the leaders of MNCs such as Pfizer Inc. (NYSE:PFE), Novartis AG (SIX:NOVN; NYSE:NVS) and Sanofi (Euronext:SAN; NASDAQ:SNY) that innovation by China biopharmas is world class, said BioCentury co-founder, President and CEO Dave Flores on the podcast.

Yu, who is the chairman of BayHelix and chairman and CEO of Apollomics Inc. (NASDAQ:APLM), discusses the importance China’s return to global in-person meetings, and Zhou, a partner at McKinsey & Co., previews one of McKinsey’s two conference reports, which will focus on the outlook for China’s innovative biopharma market.

BioCentury Editor in Chief Simone Fishburn and Executive Director of Josh Berlin also join the podcast to discuss the importance of globalization for biopharma companies and patients, and analyze trends in recent cross-border deals.

Panelists and speakers at the event include Sanofi CEO Paul Hudson; Sam Thong, chairman and co-head of healthcare investment banking, Asia ex-Japan, at Goldman Sachs; and Samuel Waksal, chairman, president and CEO, Graviton Bioscience Corp.; plus Qiming Venture Partners’ Nisa Leung and Goodwin’s Wendy Pan.

The 10th annual BioCentury-BayHelix China Healthcare Summit is Nov. 2-3 in Shanghai. Digital passes are also available.